38353-06-9

Basic information

• Product Name: 5-Bromo-2-hydroxypyrimidine
• Synonyms: 5-Bromo-1,2-dihydropyrimidine-2-one;5-Bromopyrimidine-2(1H)-one;5-Bromo-pyrimidine-2-ol;5-Bromopyrimidine-2-ol;5-Bromo-1,2-dihydro-2-oxopyrimidine;NSC 528730;5-Bromo-2-pyrimidinol 5-Bromo-2(1H)-pyrimidinone;2-hydroxy-5-broMopyriMidine(5-broMo-2-hydroxypyriMidine)
• CAS NO: 38353-06-9
• Molecular Formula: C₄H₃BrN₂O
• Molecular Weight: 174.98
• EINECS: 253-896-2
• Product Categories: Aromatics Compounds;Aromatics;Bases & Related Reagents;Nucleotides;Building Blocks;Halogenated Heterocycles;Heterocyclic Building Blocks;Pyrimidines;PyrimidinesHeterocyclic Building Blocks;Heterocycle-Pyrimidine series;Pyrimidine;Halogenated;Organohalides
• Mol File: 38353-06-9.mol
• Article Data: 23

Chemical Properties

• Melting Point: 230 °C (dec.)(lit.)
• Boiling Point: 371.3 °C at 760 mmHg
• Flash Point: 178.4 °C
• Appearance: /
• Density: 2 g/cm³
• Vapor Pressure: 4.87E-06mmHg at 25°C
• Refractive Index: 1.678
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 7.62±0.10(Predicted)
• BRN: 742202
• CAS DataBase Reference: 5-Bromo-2-hydroxypyrimidine(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Bromo-2-hydroxypyrimidine(38353-06-9)
• EPA Substance Registry System: 5-Bromo-2-hydroxypyrimidine(38353-06-9)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36
• WGK Germany: 3
• TSCA: Yes
• HazardClass: IRRITANT
• Hazardous Substances Data: 38353-06-9(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
5-Bromo-2-hydroxypyrimidine is used as a synthetic building block for the creation of more complex organic molecules. Its unique structure and reactivity make it a versatile compound in the synthesis of various organic compounds, including pharmaceuticals, agrochemicals, and other specialty chemicals.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 5-Bromo-2-hydroxypyrimidine is used as an intermediate in the development of new drugs. Its specific chemical properties allow it to be a key component in the synthesis of therapeutic agents, potentially contributing to the treatment of various diseases and medical conditions.
Used in Research and Development:
5-Bromo-2-hydroxypyrimidine is also utilized in research and development settings, where it serves as a valuable tool for understanding the fundamental chemical reactions and mechanisms involved in organic synthesis. This knowledge can be applied to the design and development of new molecules with specific properties and applications.
Used in Chemical Education:
As an instructive compound, 5-Bromo-2-hydroxypyrimidine is employed in educational settings to teach students about the principles of organic chemistry, reaction mechanisms, and the synthesis of complex molecules. Its distinct properties and reactivity make it an ideal subject for laboratory experiments and demonstrations.

InChI:InChI=1/C4H3BrN2O/c5-3-1-6-4(8)7-2-3/h1-2H,(H,6,7,8)

Upstream product

• 557-01-7 Pyrimidin-2(1H)-one 
• 14001-67-3 5-bromo-2-methylthiopyrimidine 
• 38353-09-2 2-hydroxypyrimidine hydrochloride 
• 62802-38-4 5-fluoro-2-(trifluoromethyl)pyrimidine 
• 7752-82-1 5-bromo-2-aminopyrimidine 
• 557-01-7 2-hydroxypyrimidine 

Downstream Products

• 63331-28-2 1-Propargyl-5-brom-pyrimid-2-on 
• 14001-66-2 5-bromo-2-methoxypyrimidine 
• 1246922-88-2 2-((5-bromopyrimidin-2-yl)oxy)ethan-1-ol 
• 69033-87-0 5-bromo-2-(4-methoxyphenoxy)-pyrimidine 
• 123089-03-2 2-(allyloxy)-5-bromopyrimidine 
• 121487-12-5 5-bromo-2-(propan-2-yloxy)pyrimidine 
• 257280-25-4 5-bromo-2-phenoxypyrimidine 
• 433683-47-7 5-bromo-2-(2,2,2-trifluoroethoxy)pyrimidine 
• 62802-38-4 5-fluoro-2-(trifluoromethyl)pyrimidine 
• 1438249-82-1 methyl {4-[(5-bromopyrimidin-2-yl)oxy]cyclohexyl}acetate 
• 1296644-72-8 C₂₃H₁₉Cl₂N₅O 
• 32779-37-6 2,5-dibromopyrimidine 
• 32779-36-5 5-Bromo-2-chloropyrimidine 
• 14248-01-2 5-bromo-1-methylpyrimidin-2(1H)-one 

Relevant articles and documents

Rates and equilibrium constants for the covalent hydration of 5-bromo-2(1H)-pyrimidinone in aqueous solution

The kinetics of bromination of the title compound (1) have been measured in aqueous solutions of pH 0-6.The change in the order of reaction which occurs around pH 2.5 is explained by 1 reacting via its covalent hydrate, 3.Furthermore, there is sufficient 3 present at equilibrium that the kinetics of its equilibration with 1 were also measured.From these two studies the extent of covalent hydration of 1 is estimated to be 5percent.Kinetic studies of the bromination of the dimethyl cation 5 and of its equilibration with the pseudobase 6 were also carried out for the purposes of comparison.The present results for 1, 3, 5 and 6 are compared to earlier results for 2-pyrimidinone and analogous derivatives.

One-step hydroxylation of aryl and heteroaryl fluorides using mechanochemistry

Simple use of KOH allows the direct F to OH exchange of aromatic and heteroaromatic substrates under mechanochemical conditions. The reaction is performed in the absence of solvent with potassium hydroxide as OH source. As a result, this approach is both more atom economical and environmentally friendly than previously described methods for this transformation.

Characterization of degradation products of macitentan under various stress conditions using liquid chromatography/mass spectrometry

Rationale: Stress testing of a drug candidate is an important step in the drug discovery and development process. The presence of degradation products in a drug affects the quality as well as the safety and efficacy of drug formulation. Hence, it is essential to develop an efficient analytical method which could be useful for the separation, identification and characterization of all possible degradation products (DPs) of a drug. Macitentan (MT) is an endothelin receptor antagonist (ERA) drug used to treat high blood pressure in the lungs. Comprehensive stress testing of MT was carried out as per ICH guidelines to understand the degradation profile of the drug. Methods: MT was subjected to various stress conditions such as acidic, basic, neutral hydrolysis, oxidation, photolysis and thermal conditions; and the resulting degradation products were investigated using liquid chromatography/diode-array detection/electrospray ionization high-resolution mass spectrometry (LC/DAD/ESI-HRMS) and tandem mass spectrometry (MS/MS) techniques. An efficient and simple ultra-high-performance liquid chromatography (UHPLC) method has been developed using an Accucore C18 column (4.6?×?150?mm, 2.6?μm) using a gradient elution of 5?mM ammonium formate and acetonitrile as mobile phases. Results: MT was found to degrade under acid and base hydrolysis stress conditions; whereas it was stable under oxidation, neutral hydrolysis, thermal and photolytic conditions. MT formed nine DPs (DP1 to DP9) and one DP (DP10) under acidic and basic hydrolytic conditions, respectively. All the degradation products (DP1 to DP10) were identified and characterized by LC/MS/MS in positive ion mode with accurate mass measurements. Conclusions: MT was found to be labile under hydrolytic conditions. The structures of the DPs were characterized by appropriate mechanisms. The proposed method can be effectively used for the characterization of MT and its DPs.

FACTOR IXA INHIBITORS

In its many embodiments, the present invention provides a novel class of benzamide compounds represented by Formula (I) or pharmaceutically acceptable salts or solvates thereof, or pharmaceutical compositions comprising one or more said compounds or pharmaceutically acceptable salts or solvates thereof, and methods for using said compounds or pharmaceutically acceptable salts or solvates thereof for treating or preventing a thromboses, embolisms, hypercoagulability or fibrotic changes.

FACTOR IXA INHIBITORS

In its many embodiments, the present invention provides a novel class of benzamide compounds represented by Formula (I) or pharmaceutically acceptable salts or solvates thereof, or pharmaceutical compositions comprising one or more said compounds or pharmaceutically acceptable salts or solvates thereof, and methods for using said compounds or pharmaceutically acceptable salts or solvates thereof for treating or preventing a thromboses, embolisms, hypercoagulability or fibrotic changes.

Synthesis, characterization and pharmacological study of 4,5-dihydropyrazolines carrying pyrimidine moiety

A series of 5-bromo-2-(3,5-diaryl-4,5-dihydro-1H-pyrazol-1-yl)pyrimidine were prepared under conventional heating as well as microwave reaction condition. The newly synthesized compounds were characterized on the basis of elemental, spectral and single crystal X-ray studies. These new compounds were screened for their antioxidant, anti-inflammatory and analgesic activities. Some of these compounds exhibited potent biological activities compared to the standard drug.

INHIBITORS OF ACETYL-COA CARBOXYLASE

The present invention relates to compounds that act as acetyl-CoA carboxylase (ACC) inhibitors. The invention also relates to methods of preparing the compounds, compositions containing the compounds, and to methods of treatment using the compounds.

2-ALKYNYL-6-PYRIDIN-2-YL-PYRIDAZINONES, 2-ALKYNYL-6-PYRIDIN-2-YL-DIHYDROPYRIDAZINONES, 2-ALKYNYL-6-PYRIMIDIN-2-YL-PYRIDAZINONES AND 2-ALKYNYL-6-PYRIMIDIN-2-YL-DIHYDROPYRIDAZINONES AND THEIR USE AS FUNGICIDES

This invention relates to certain novel 2-alkynyl-6-pyridin-2-yl-pyridazinones, 2-alkynyl-6-pyridin-2-yl-dihydropyridazinones, 2-alkynyl-6-pyrimidin-2-yl-pyridazinones and 2-alkynyl-6-pyrimidin-2-yl-dihydropyridazinones and to the use of these compounds for control of fungal pathogens of plants and mammals.

INDOLES USEFUL IN THE TREATMENT OF INFLAMMATION

There is provided a compound of formula: (I), wherein X, R1, R2, R3, R4, R5 and R6 have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of the activity of microsomal prostaglandin E synthase-1 is desired and/or required, and particularly in the treatment of inflammation.

Novel diazine derivatives

The present invention provides compounds of formula (I): their pharmaceutically acceptable salts or esters, enantiomeric forms, diastereoisomers and racemates, the preparation of the above-mentioned compounds, pharmaceutical compositions containing them and their manufacture, as well as the use of the above-mentioned compounds in the control or prevention of illnesses such as cancer.